8-cyclopentyl-3-(3-((4-(fluorosulfonyl)benzoyl)oxy)propyl)-1-propylxanthine has been researched along with cimetidine in 3 studies
| Studies (8-cyclopentyl-3-(3-((4-(fluorosulfonyl)benzoyl)oxy)propyl)-1-propylxanthine) | Trials (8-cyclopentyl-3-(3-((4-(fluorosulfonyl)benzoyl)oxy)propyl)-1-propylxanthine) | Recent Studies (post-2010) (8-cyclopentyl-3-(3-((4-(fluorosulfonyl)benzoyl)oxy)propyl)-1-propylxanthine) | Studies (cimetidine) | Trials (cimetidine) | Recent Studies (post-2010) (cimetidine) |
|---|---|---|---|---|---|
| 28 | 0 | 12 | 9,473 | 1,687 | 377 |
| Protein | Taxonomy | 8-cyclopentyl-3-(3-((4-(fluorosulfonyl)benzoyl)oxy)propyl)-1-propylxanthine (IC50) | cimetidine (IC50) |
|---|---|---|---|
| Solute carrier family 22 member 1 | Mus musculus (house mouse) | 0.59 | |
| Solute carrier family 22 member 2 | Mus musculus (house mouse) | 8 | |
| Potassium-transporting ATPase alpha chain 1 | Homo sapiens (human) | 0.82 | |
| Histamine H2 receptor | Homo sapiens (human) | 1.1742 | |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | 1.02 | |
| Potassium-transporting ATPase subunit beta | Homo sapiens (human) | 0.82 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 3.0333 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
| Alhaj, M; Bozarov, A; Christofi, FL; Cooke, HJ; Grants, I; Hassanain, HH; Ren, T; Wang, YZ; Wunderlich, J; Yu, JG | 1 |
3 other study(ies) available for 8-cyclopentyl-3-(3-((4-(fluorosulfonyl)benzoyl)oxy)propyl)-1-propylxanthine and cimetidine
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |
Activation of adenosine low-affinity A3 receptors inhibits the enteric short interplexus neural circuit triggered by histamine.
Topics: Adenosine; Animals; Chlorides; Cimetidine; Colon; Dihydropyridines; Dimaprit; Dose-Response Relationship, Drug; Enteric Nervous System; Gastrointestinal Motility; Guinea Pigs; Histamine; Histamine Agonists; Histamine H2 Antagonists; In Vitro Techniques; Intestinal Secretions; Male; Mecamylamine; Muscle Contraction; Muscle Relaxation; Muscle, Smooth; Neural Inhibition; Neurogenic Bowel; Neurokinin-1 Receptor Antagonists; Nicotinic Antagonists; Piperidines; Propane; Receptor, Adenosine A1; Receptor, Adenosine A3; Receptors, Histamine H2; Receptors, Neurokinin-1; Reflex; Theophylline; Xanthines | 2009 |